Bio-business in brief: a case for new drugs at generic prices from India

The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate p...

Full description

Saved in:
Bibliographic Details
Published in:Current science (Bangalore) 2012-05, Vol.102 (10), p.1375-1381
Main Authors: Venkatachalam, Suri, Saberwal, Gayatri
Format: Article
Language:English
Subjects:
Business structures
Complementary therapies
Drug discovery
Funding
GENERAL ARTICLES
Generic drugs
Health care industry
Molecules
Multilateralism
Nonprofit organizations
Philanthropy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate partners, and working primarily in India, it could lower the cost of innovation. Funding could be from a variety of players that expect a social, not financial, return. The drugs thus developed could be licensed out to a limited number of generic pharma companies, and thus be available at generic prices immediately.
ISSN:0011-3891